Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408005 | 0.90 | OPRD1 (0.68) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL29932500 | 0.89 | CASP1 (0.63) | OPRD1CASP1BACE1BACE2 | |
| SCHEMBL4735755 | 0.89 | OPRD1 (0.65) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL31404908 | 0.88 | OPRD1 (0.66) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL4735748 | 0.88 | OPRD1 (0.61) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL478003 | 0.85 | OPRD1 (0.62) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL30079821 | 0.83 | OPRD1 (0.58) | OPRD1BACE1BACE2OPRM1OPRK1 | |
| SCHEMBL1170338 | 0.83 | OPRD1 (0.60) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL31257068 | 0.83 | OPRD1 (0.64) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL17557404 | 0.82 | CASP1 (0.67) | OPRD1CASP1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629415-B2 | Vaccine adjuvants | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2026-05-19 | — | — | US | disclosed |
| US-20250288542-A1 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-18 | — | — | US | disclosed |
| WO-2024153585-A1 | SELECTIVE CASPASE-8 INHIBITORS AND USES THEREOF IN AUGMENTING INNATE IMMUNE DEFENSES | SCYLLA BIOTECH SRL (IT) | 2024-07-25 | — | — | WO | disclosed |
| CN-117442733-B | Application of IRF7 expression inhibitor in preparation of medicine for preventing and treating reproduction toxicity caused by 1,2-dichloroethane | 南方医科大学 | 2024-03-29 | — | — | CN | disclosed |
| US-11932908-B2 | Compositions and methods for diagnosis and treatment of epilepsy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-19 | — | — | US | disclosed |
| CN-117442733-A | Application of IRF7 expression inhibitor in preparation of medicine for preventing and treating reproduction toxicity caused by 1,2-dichloroethane | 南方医科大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-3558335-B1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP AID INC (CA) | 2023-04-19 | — | — | EP | disclosed |
| US-20230032473-A1 | NAD(H) NANOPARTICLES AND METHODS OF USE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-02-02 | — | — | US | disclosed |
| CN-110462401-B | Use of enhancers of cellular autophagy for sensitizing tumors to radiotherapy | 古斯塔夫·鲁西研究所 | 2023-01-17 | — | — | CN | disclosed |
| US-11517575-B2 | Use of minaprine to reduce tumor growth | INSTITUT GUSTAVE ROUSSY (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11471463-B2 | Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy | INSTITUT GUSTAVE ROUSSY (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20220251158-A1 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2022-08-11 | — | — | US | disclosed |
| EP-3990002-A1 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | Universitat de Lleida (ES) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022072745-A1 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP-AID INC. (CA) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517575-B2 | Use of minaprine to reduce tumor growth | METAP1, METAP2, CMA1 | OPRD1 932/4885CASP1 2678/4885BACE1 3827/4885 |
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP1, CASP5, CASP10 | OPRD1 4452/4885CASP1 1/4885BACE1 4/4885 |
| US-11471463-B2 | Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy | CMA1, LY96, CD74 | OPRD1 2109/4885CASP1 1002/4885BACE1 4032/4885 |
| US-12629415-B2 | Vaccine adjuvants | STING1, TLR9, TLR3 | OPRD1 1682/4885CASP1 97/4885BACE1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.